IGWM
GRCE

ICA Group Wealth Management’s Grace Therapeutics GRCE Stock Holding History

ICA Group Wealth Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9
Closed -$26 – 1428
2023
Q4 		$26 Buy
+9
New +$21 ﹤0.01% 1336
2023
Q3 		– Sell
-10
Closed -$29 – 1286
2023
Q2 		$29 Hold
10
– – ﹤0.01% 1328
2023
Q1 		$26 Hold
10
– – ﹤0.01% 1268
2022
Q4 		$29 Buy
+10
New +$29 ﹤0.01% 1311

Other funds holding GRCE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

ICA Group Wealth Management's GRCE Position: Q1 2024 in Review

ICA Group Wealth Management sold out of Grace Therapeutics (GRCE) in Q1 2024, closing a stake of 9 shares — an estimated $26 sold.

ICA Group Wealth Management first reported a position in GRCE in Q4 2022 and held it in 4 quarters. The position peaked at $29 in Q2 2023. 10 funds tracked by Wall St. Rank hold GRCE as of Q1 2024.

  • ICA Group Wealth Management reported no remaining Grace Therapeutics position as of Q1 2024 after selling out during the quarter.
  • ICA Group Wealth Management sold 9 Grace Therapeutics shares in Q1 2024, an estimated $26.
  • ICA Group Wealth Management first reported a position in Grace Therapeutics in Q4 2022 and held it in 4 quarters.
  • ICA Group Wealth Management's Grace Therapeutics position peaked at $29 in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2024.

Based on ICA Group Wealth Management's 13F filing for Q1 2024, filed 14 May 2024.